CavGene Therapeutics

Gene therapy to prevent or delay the onset of levodopa-induced dyskinesias in individuals with Parkinson’s disease.

What We Do

Founded in November of 2022, CavGene Therapeutics, Inc. is a pre-clinical stage gene therapy company headquartered in East Lansing Michigan. The company is developing proprietary AAV based RNA interference (RNAi) targeting specific L-type calcium channel isoforms in the brain for the treatment of debilitating neurodegenerative disease.

The,Human,Brain.,The,Study,Of,The,Possibilities,Of,The

Mission Statement

CavGene Therapeutics, using innovative science to selectively target and silence specific calcium channels in the brain to provide life-transforming treatment of neurodegenerative disease, enhancing quality of life and reducing caregiver burden.

Vision Statement

To become a world leader in the science and gene therapy-based targeting of L-type calcium channels in the treatment of debilitating neurodegenerative disorders.